Homepage

Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 MM
MPN RESEARCH FUNDED
0
RESEARCHERS SUPPORTED
0
PROJECTS FUNDED

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • Identifying and Validating Actionable Biomarkers in MPN  

    MPN NEWS | May 25, 2022

    Research Spotlight on Rebekka Schneider, MD, Director, Department of Cell and Tumor Biology, Aachen University, Germany, and Erasmus MC Cancer Institute, The Netherlands. In MPNs, your blood forming stem cell acquires a mutation, and this leads to more proliferation. In the beginning, you have too many blood cells. Then, in the course of the disease,… Read More »Identifying and Validating Actionable Biomarkers in MPN  

    READ MORE

    MPN Research Foundation and Trialjectory Partner to Provide Advanced Clinical Trial Matching Services for Patients in Need

    MPN NEWS | May 10, 2022

    New York, N.Y., May 10, 2022 – The MPN Research Foundation (MPNRF), a global organization driving research to find new and better treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers, and Trialjectory, the AI-powered decision-support platform for patients, healthcare providers and pharmaceutical companies, today announced a joint collaboration to bring Trialjectory’s free,… Read More »MPN Research Foundation and Trialjectory Partner to Provide Advanced Clinical Trial Matching Services for Patients in Need

    READ MORE

    Bridging a Patient’s Mutational Data and Clinical Observations to Help Predict Progression

    MPN NEWS | May 2, 2022

    PhD Stanford University With so much variability of symptoms and progression among MPN patients, individualized treatment plans are critical in the management of essential thrombocythemia, polycythemia vera, and myelofibrosis. Personalized medicine in MPNs requires that we first address the challenge of patient genetic heterogeneity, according to Anandi Krishnan, PhD, including across the clinical spectrum of… Read More »Bridging a Patient’s Mutational Data and Clinical Observations to Help Predict Progression

    READ MORE
  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With your generous gift, you can change a MPN patient’s prognosis.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.

    DONATE NOW

    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    Under the Microscope